Reply by Authors.

Saved in:
Bibliographic Details
Title: Reply by Authors.
Authors: Yerram NK; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Long L; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., O'Connor LP; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Wang AZ; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Lebastchi AH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Zeng J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Chalfin H; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Harmon SA; Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland., Mehralivand S; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Merino MJ; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Parnes HL; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Choyke PL; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Shih J; Division of Cancer Prevention, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland., Wood BJ; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Turkbey B; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Source: The Journal of urology [J Urol] 2021 May; Vol. 205 (5), pp. 1359-1360. Date of Electronic Publication: 2021 Mar 11.
Publication Type: Journal Article; Comment
Journal Info: Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-3792
DOI:10.1097/JU.0000000000001547.03